KKR's Health Care Co-Head Ali Satvat on Investing In Health Care

The transcript discusses the challenges and opportunities in vaccine trials, emphasizing the need for ongoing trials due to vaccine tweaking. It highlights the resilience of healthcare and the potential of telemedicine and socialized healthcare post-COVID. The impact of COVID on healthcare valuations and investment opportunities is also explored, with a focus on innovation and growth in the sector.

What is a major concern regarding vaccine trials once vaccines are widely available?

• Trials will be too lengthy.

• There will be a shortage of vaccines.

• Trials will become too expensive.

• People may not want to participate in trials.

Why might ongoing trials be necessary for vaccines?

• To reduce the number of doses required.

• To tweak and reformulate vaccines for better efficacy.

• To make vaccines more accessible.

• To ensure vaccines are affordable.

What are two significant changes in healthcare due to COVID-19?

• Growth in telemedicine and discussions on socialized healthcare.

• Reduction in healthcare spending.

• Decreased focus on healthcare innovation.

• Increased hospital visits and reduced telemedicine.

How has COVID-19 affected the healthcare supply chain?

• It has eliminated supply chain issues.

• It has reduced the need for a supply chain.

• It has made the supply chain more efficient.

• It has highlighted vulnerabilities in the supply chain.

What has COVID-19 reminded investors about healthcare?

• Healthcare will not see any growth.

• Healthcare investments are too risky.

• Healthcare is a stable and important sector.

• Healthcare is not a priority.

What is a key factor driving investment in healthcare?

• Decreasing demand for healthcare.

• The need for innovative products and services.

• High costs of healthcare.

• Lack of innovation.

What is the outlook on healthcare investments post-COVID-19?

• Healthcare will no longer be a viable investment.

• Investments are expected to decline.

• There is a positive outlook due to innovation and growth opportunities.

• Investments will remain stagnant.